Literature DB >> 26833042

Repetitive restriction of muscle blood flow enhances mTOR signaling pathways in a rat model.

Toshiaki Nakajima1, Tomohiro Yasuda2, Seiichiro Koide3, Tatsuya Yamasoba4, Syotaro Obi5, Shigeru Toyoda6, Yoshiaki Sato7, Teruo Inoue6, Yutaka Kano3.   

Abstract

Skeletal muscle is a plastic organ that adapts its mass to various stresses by affecting pathways that regulate protein synthesis and degradation. This study investigated the effects of repetitive restriction of muscle blood flow (RRMBF) on microvascular oxygen pressure (PmvO2), mammalian target of rapamycin (mTOR) signaling pathways, and transcripts associated with proteolysis in rat skeletal muscle. Eleven-week-old male Wistar rats under anesthesia underwent six RRMBF consisting of an external compressive force of 100 mmHg for 5 min applied to the proximal portion of the right thigh, each followed by 3 min rest. During RRMBF, PmvO2 was measured by phosphorescence quenching techniques. The total RNA and protein of the tibialis anterior muscle were obtained from control rats, and rats treated with RRMBF 0-6 h after the stimuli. The protein expression and phosphorylation of various signaling proteins were determined by western blotting. The mRNA expression level was measured by real-time RT-PCR analysis. The total muscle weight increased in rats 0 h after RRMBF, but not in rats 1-6 h. During RRMBF, PmvO2 significantly decreased (36.1 ± 5.7 to 5.9 ± 1.7 torr), and recovered at rest period. RRMBF significantly increased phosphorylation of p70 S6-kinase (p70S6k), a downstream target of mTOR, and ribosomal protein S6 1 h after the stimuli. The protein level of REDD1 and phosphorylation of AMPK and MAPKs did not change. The mRNA expression levels of FOXO3a, MuRF-1, and myostatin were not significantly altered. These results suggested that RRMBF significantly decreased PmvO2, and enhanced mTOR signaling pathways in skeletal muscle using a rat model, which may play a role in diminishing muscle atrophy under various conditions in human studies.

Entities:  

Keywords:  Blood flow restriction; Hypoxia; Mammalian target of rapamycin (mTOR); Microvascular pO2; Muscle atrophy; Myostatin; Rat skeletal muscle; p70 S6-kinase

Mesh:

Substances:

Year:  2016        PMID: 26833042     DOI: 10.1007/s00380-016-0801-6

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  58 in total

1.  Modulation of myostatin expression during modified muscle use.

Authors:  M Wehling; B Cai; J G Tidball
Journal:  FASEB J       Date:  2000-01       Impact factor: 5.191

2.  Human skeletal muscle intracellular oxygenation: the impact of ambient oxygen availability.

Authors:  Russell S Richardson; Sandrine Duteil; Claire Wary; D Walter Wray; Jan Hoff; Pierre G Carlier
Journal:  J Physiol       Date:  2006-01-05       Impact factor: 5.182

3.  Implication of phosphatidylinositol 3-kinase membrane recruitment in hydrogen peroxide-induced activation of PI3K and Akt.

Authors:  Suofu Qin; P Boon Chock
Journal:  Biochemistry       Date:  2003-03-18       Impact factor: 3.162

4.  Imaging of phosphorescence: a novel method for measuring oxygen distribution in perfused tissue.

Authors:  W L Rumsey; J M Vanderkooi; D F Wilson
Journal:  Science       Date:  1988-09-23       Impact factor: 47.728

Review 5.  Control of the hypoxic response through regulation of mRNA translation.

Authors:  Bradly G Wouters; Twan van den Beucken; Michael G Magagnin; Marianne Koritzinsky; Diane Fels; Constantinos Koumenis
Journal:  Semin Cell Dev Biol       Date:  2005 Aug-Oct       Impact factor: 7.727

6.  Applications of vascular occlusion diminish disuse atrophy of knee extensor muscles.

Authors:  Y Takarada; H Takazawa; N Ishii
Journal:  Med Sci Sports Exerc       Date:  2000-12       Impact factor: 5.411

7.  A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets.

Authors:  Andrew M Arsham; Jessica J Howell; M Celeste Simon
Journal:  J Biol Chem       Date:  2003-05-30       Impact factor: 5.157

8.  Histological skeletal muscle damage and surface EMG relationships following eccentric contractions.

Authors:  Yutaka Kano; Kazumi Masuda; Hirotaka Furukawa; Mizuki Sudo; Kazuyuki Mito; Kazuyoshi Sakamoto
Journal:  J Physiol Sci       Date:  2008-10-07       Impact factor: 2.781

9.  Prevention of disuse muscular weakness by restriction of blood flow.

Authors:  Atsushi Kubota; Keishoku Sakuraba; Keisuke Sawaki; Takahiro Sumide; Yoshifumi Tamura
Journal:  Med Sci Sports Exerc       Date:  2008-03       Impact factor: 5.411

10.  Human muscle gene expression following resistance exercise and blood flow restriction.

Authors:  Micah J Drummond; Satoshi Fujita; Takashi Abe; Abe Takashi; Hans C Dreyer; Elena Volpi; Blake B Rasmussen
Journal:  Med Sci Sports Exerc       Date:  2008-04       Impact factor: 5.411

View more
  4 in total

Review 1.  Selected Methods of Resistance Training for Prevention and Treatment of Sarcopenia.

Authors:  Tomohiro Yasuda
Journal:  Cells       Date:  2022-04-20       Impact factor: 7.666

2.  Unilateral, bilateral, and alternating muscle actions elicit similar muscular responses during low load blood flow restriction exercise.

Authors:  Daphney M Stanford; Joonsun Park; Matthew B Jessee
Journal:  Eur J Appl Physiol       Date:  2021-06-30       Impact factor: 3.078

3.  Blood Flow Restriction Only Increases Myofibrillar Protein Synthesis with Exercise.

Authors:  Jean Nyakayiru; Cas J Fuchs; Jorn Trommelen; Joey S J Smeets; Joan M Senden; Annemie P Gijsen; Antoine H Zorenc; Luc J C VAN Loon; Lex B Verdijk
Journal:  Med Sci Sports Exerc       Date:  2019-06       Impact factor: 5.411

4.  Repetitive vascular occlusion stimulus (RVOS) versus standard care to prevent muscle wasting in critically ill patients (ROSProx):a study protocol for a pilot randomised controlled trial.

Authors:  Ismita Chhetri; Julie E A Hunt; Jeewaka R Mendis; Stephen D Patterson; Zudin A Puthucheary; Hugh E Montgomery; Benedict C Creagh-Brown
Journal:  Trials       Date:  2019-07-24       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.